Answers are grounded in this paper and cite their sources.
Keynote highlights AI's governance challenges in innovation and risk management in China.
[***Risk Sciences***](https://www.keaipublishing.com/en/journals/risk-sciences/) aims to foster diverse, multidisciplinary insights in risk sciences, bridging theory and practice through a series of academic activities. Professor Liang's research interests primarily lie in science, technology and innovation policy, globalization of R D, intellectual property rights and standardization, and the governance of emerging technologies and innovation. This speech record is an excerpt from Professor Liang's keynote speech for the [Risk Sciences Colloquium – Artificial Intelligence and Risk Management](https://www.keaipublishing.com/en/journals/risk-sciences/event/risk-sciences-colloquium-artificial-intelligence-and-risk-management/) , which was held on September, 26, 2025, in Beijing, China.
No takes yet. Share an insight, caveat, or question.
Liang Zheng (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: